MASH and MASLD development must constantly shift to meet the changing regulatory expectations and therapeutic approaches that collectively reshape clinical trials. Worldwide incorporates endpoint strategy into the protocol from the beginning, informing each component of the trial for long-term success. Our liver team uses combined hepatology expertise and operational support to help sponsors build studies around today’s requirements and prepare for the future.
We’ll connect you with the right liver and metabolic experts.
Why MASH & MASLD Programs Demand Specialized Support
Worldwide combines integrated liver and metabolic expertise, in-house biopsy management, and experience with both histologic and non-invasive endpoints to support modern MASH and MASLD development. This coordinated approach helps sponsors navigate evolving regulatory expectations, reduce operational complexity, and generate high-quality data with confidence.
As approved therapies reshape the MASH landscape, new programs require clear scientific differentiation and endpoint strategies that extend beyond biopsy alone. Worldwide combines liver and metabolic expertise to support histologic, biomarker, imaging, and non-invasive endpoint approaches.
F2/F3 and F4 populations present distinct scientific and operational considerations that directly affect study design and execution. Worldwide applies rigorous oversight of stratification, biomarker assessment, and non-invasive testing across sites and central laboratories to support accurate patient selection and high-quality endpoint data.
The growing overlap between obesity, GLP-1 therapies, and MASH requires integrated liver and metabolic expertise. Worldwide supports programs with coordinated scientific leadership and experience incorporating MRI-PDFF, non-invasive assessments, and emerging endpoint strategies into modern MASH trial design.

Partnership & Approach
Sponsors work with the same liver-experienced scientific, medical, and operational leaders throughout the life of the program. With more than 150 years of combined liver disease research experience, Worldwide provides the continuity, expertise, and strategic partnership needed to guide complex MASH and MASLD studies from startup through final results.
A global liver development track record spanning indications, phases, and geographies, from early-phase clinical research through multinational Phase III studies. Worldwide combines scientific expertise, operational rigor, and integrated liver-metabolic leadership to support successful program execution at every stage of development.
Subjects
Sites
A Phase III MASH program delivered with biopsy management, MRI-PDFF, FibroScan®, and biomarker composite scoring integrated throughout.

Years of Combined Liver Experience
Across MASH, MASLD, PSC, PBC, and rare liver disease programs, with consultation on endpoint selection, surrogate endpoints, stratification and enrichment.

Established Liver Site Partnerships
Direct access to high-performing investigators and proven liver trial sites across 30+ countries.

Why Worldwide for MASH and MASLD Trials
More than 500 established liver site partnerships provide direct access to experienced MASH and MASLD investigators, supporting faster startup, stronger recruitment performance, and efficient execution across global Phase III programs.
Worldwide’s dedicated liver team oversees biopsy collection and management, while MRI-PDFF, MRE, FibroScan®, and biomarker-based endpoint strategies are coordinated under the same scientific leadership. This integrated approach supports consistent endpoint quality, operational efficiency, and data integrity.
Whether you need a fully outsourced MASH program or targeted functional support, Worldwide provides a dedicated liver team that stays with your study from startup through final analysis. The result is greater flexibility, consistent expertise, and a partnership model that scales alongside your program.
Frequently Asked Questions
We’ve answered the questions sponsors ask most often about MASH and MASLD clinical development. If your question isn’t covered here, our liver disease experts are available to discuss your program’s specific scientific, regulatory, and operational needs.
Worldwide’s MASH experience spans Phase I-III development, including a 1,690-subject Phase III study across 150 sites and multiple global Phase II programs. Our teams support biopsy management, MRI-PDFF, FibroScan®, biomarker composite scoring, and integrated liver-metabolic development strategies across every stage of clinical development.
The MASH landscape is constantly changing alongside regulatory expectations, approved therapies, and emerging non-invasive technologies, which change clinical development expectations. Worldwide’s experts monitor FDA and EMA guidance to incorporate it into trial design from the outset. Sponsors require approaches and non-invasive strategies that provide a comprehensive understanding of treatment effect. Worldwide helps sponsors design robust, sustainable programs, drawing from our expertise in endpoint strategy and future planning.
Worldwide manages liver biopsy collection, processing, tracking and interpretation within our dedicated liver team rather than relying on fragmented outsourcing models. Biopsy oversight is integrated with MRI-PDFF, MRE and FibroScan imaging, as well as key biomarker assessments including MASH Fibrosis Score, FIB-4, APRI, FibroSURE/FibroTest and ELF. By bringing centralized biopsy management, AI-assisted histopathology review and scientific leadership under a single operational framework, we help ensure consistency, quality and endpoint integrity across MASH and MASLD programs.
Screen failure runs higher in IgA nephropathy than most enrollment models assume, and competition for biopsy-confirmed patients is heaviest in the U.S. A pre-selected pool of sites gives the program room to move when rates run high, supported by site-level recruitment strategies, patient education materials and patient reimbursement services. On a Phase II cross-over study, that approach closed enrollment 6 months ahead of schedule across 30 sites in 6 countries.